JYMed is pleased to announce that the U.S. Food and Drug Administration has acknowledged receipt of a new Type II Drug Master File for semaglutide API manufactured under a new process.

This filing reflects our continued commitment to strengthening technical capabilities, process development, and regulatory support for complex peptide APIs. As global demand for high-quality semaglutide continues to grow, JYMed remains focused on supporting partners with robust manufacturing expertise, regulatory documentation, and scalable supply solutions.

The newly filed DMF further demonstrates JYMed’s ongoing investment in peptide process optimization and regulatory readiness. For partners evaluating long-term supply strategies, this milestone supports broader confidence in our ability to advance high-standard manufacturing programs for strategically important peptide APIs.

At JYMed, we continue to expand our platform for peptide development and manufacturing, with a focus on quality, consistency, and international regulatory support. We look forward to continuing to support customers seeking reliable peptide API partners for both current and future pipeline needs.

Important Disclaimer:
The FDA’s acknowledgment of the new semaglutide active pharmaceutical ingredient process is only a necessary preliminary regulatory step. Final market approval and international commercialization remain subject to further complex review and registration procedures, and the timing and outcome of those processes are uncertain.

To learn more about JYMed’s peptide API and CDMO capabilities, contact our team to discuss your peptide development needs.